Enterococcal Infection in the ICU: At the Precipice of a Postantibiotic Era Peter K. Linden, MD Linden PK Enterococcal Infection in the ICU At the Precipice of a Postantibiotic Era J Intensive Care Med 1999,14 59-61 The genus Enterococcus has achieved remarkable prominence as a nosocomial and ICU pathogen during the last two decades and has overcome the long-held perception that these organisms were only contaminants, saprophytes, or pathogens with a low clinical impact. The excellent, contemporaneous review by Drs. Ostrowsky and Eliopoulos on enterococcal infection in this issue of the journal of Intensive Care Medicine appropriately focuses on the modus operandi of this hardy organism; intrinsic antimicrobial resistance compounded with an uncanny ability to acquire additional resistance mechanisms to a diverse spectrum of antimicrobials culminating in pan resistance to all available agents with the emergence of vancomycin resistance among E. faecium and to a lesser extent strains of E. faecalis. Although in retrospect it should come as little surprise that the Enterococcus has become the first nosocomial bacterial organism to achieve pan resistance on such a wide scale, there was no expert consensus which predicted its first occurrence in 1986 in France or foresaw its rapid proliferation in the United States since 1989. This phenomenon is in fact related to its ability to evade antimicrobial activity and, just as importantly, a more opportunistic clinical environment for this relatively low-virulence pathogen to flourish.
For ICU clinicians, the most fundamental questions raised by these developments are what factors initiated and accelerated this trend, how has it influenced our current practice and patient outcome, and what future therapeutic and control options will be available?
The complex patients present in our ICUs today are both a fertile breeding ground for such organisms and a most susceptible target for serious infection from them. The increased incidence of nosocomial enterococcal infection is one compo-From the University of Pittsburgh Medical Center, Division of Critical Care Medicme, Pittsburgh, PA Address correspondence to Dr Peter Linden, University of Pittsburgh Medical Center, Division of Critical Care Medicine, 3550 Terrace St, 615 Scaife Hall, Pittsburgh, PA 15261, or e-mail hnden&reg;stmp anes.upmc edu nent of a larger ecological shift within the past two decades which has witnessed the dominance of gram-positive species and strains exhibiting resistance to multiple antimicrobials. Between the years 1980 and 1989 the National Nosocomial Infection Surveillance System (NNIS) reported a 754% increase in the incidence of bloodstream infection due to coagulase-negative staphylococci followed by a 176% and 124% increase for S. aureus and enterococci, respectively, at large academic centers [1] . More recent surveillance studies such as the Surveillance and Control of Pathogens of Epidemiologic Importance (SCOPE) revealed that coagulasenegative staphylococci, S aureus, and enterococci were, respectively, the three most frequent nosocomial bloodstream isolates and together accounted for 59.4% of nosocomial bacteremias [2] . Methicillin resistance was present in 79% of coagulase-negative staphylococci and 28% of S. aureus, while vancomycin resistance was present in 17% of enterococci and almost 50% of E. faecium isolates. Both the gram-positive and antimicrobial-resistance trends are fundamentally due to three naturally coupled factors: an increased prevalence of sicker patients with compromised local and/or systemic host defenses ; a greater reliance on the use of invasive devices, particularly indwelling intravascular devices, and other artificial support systems (hemodialysis, mechanical ventilation); and increased use (both appropriate and inappropriate) of broad spectrum antimicrobials with gram-positive selective properties, that is, cephalosporins and imipenem-cilastatin. Moreover, the increasing burden of methicillin-resistant staphylococcal infection has stereotypically limited therapy to only vancomycin and resulted in an astounding 20-fold increase in the use of this agent since the early 1980s [3] . Vancomycin administration has been shown to increase the VRE inoculum by a 6-8 log magnitude in persons with a low level of intestinal VRE colonization [4] . Thus antecedent vancomycin use has been a risk factor in most, but not all, case control studies assessing risk factors for VRE infection. The ubiquity of vancomycin use and misuse in the contemporary ICU remains one of the dominant hurdles for the control of VRE and future multiresistant grampositive strains.
How has the emergence of multiresistant enterococci affected ICU clinical practice and patient outcome ? It has bccn said that enterococci infect sick patients and vancomycin-resistant enterococci infect the sickest patients. A review of multiple VRE series in recent years confirms that these strains are epidemiologically selective for patients with chronic and acute comorbidity. The disproportionately higher incidence of VRE infection in ICU, transplant, and oncologic patients is ample evidence for this effect. The review by Drs. Ostrowsky and Eliopoulos emphasizes that there is no evidence that such multiresistant strains possess a higher intrinsic virulence than more susceptible enterococcal strains. Thus any additional morbidity and mortality due to resistance could occur due to a sicker target population, the loss of antimicrobial therapeutic options, or a greater reliance on invasive therapeutic alternatives which are in and of themselves associated with more complications, that is, repetitive surgery, permanent device removal. Studies comparing the outcome of grampositive bacteremia due to susceptible and resistant phenotypes of S. aureus (MRSA versus MSSA) and enterococci (high-level aminoglycoside resistant versus high-level aminoglycoside susceptible) prior to the emergence of VRE fail to show a significant difference in outcome when adjustments for comorbidity were performed [5] [6] [7] [8] .
Recent comparisons of outcome of infection due to &dquo;treatable&dquo; vancomycin-susceptible enterococci to &dquo;untreatable&dquo; VRE have shown mixed results [9] [10] [11] [12] . Several series have shown that vancomycin resistance was an independent predictor of worse outcome, while others have not discerned any difference. The case mix of patients plays a major determinant role; liver and other solid organ recipients, neutropenic patients, and patients with a higher APACHE II score consistently fared worse. Intuitively this is expected because such patients experience the combined loss of host and pharmaceutical defense mechanisms.
Isolation of VRE does not obligate antimicrobial therapy since a clinical response can be achieved with conservative measures alone such as catheter removal or wound debridement [13] . Optimal therapy for serious enterococcal infection has traditionally been a cell-wall active agent (beta-lactam) coupled with an aminoglycoside to achieve bactericidal synergy, although even single-agent bacteriostatic treatment has been shown to improve outcome [14] . Paradoxically, with the emergence of VRE, the first reflex of many clinicians has been to reach for antiquated antimicrobials with in vitro activity against the infecting VRE strain. Published case reports using antimicrobial agents popular in the 1950s and 1960s, such as bacitracin, novobiocin, tetracycline, and chloramphenicol with rifampin, have shown mixed results and over time do not appear to provide sustained treatment strategies due to the development of resistance, toxicity, and superinfection [15] [16] [17] [18] .
The pharmaceutical industry has finally responded to the multiresistant gram-positive challenge with a variety of unique investigational compounds, including quinupristin/dalfopristin, linezolid, everninomycin, and others. Quinupristin/dalfopristin has advanced the farthest in clinical trials and has shown a 70% rate of clinical response for VRE infection in a still ongoing noncomparative emergency use trial. Interpretation of such data is problematic due to the &dquo;comparison vacuum&dquo; that exists in the absence of a standard comparator. Thus if randomized clinical trials comparing two different agents are not possible, innovative variable-dose response trials will be needed for these new agents to measure both efficacy and toxicity. Enthusiasm for these promising new agents should be tempered by the realization that within the current decade clinical investigation of several new compounds with gram-positive activity (teicoplanin, daptomycin, ramoplanin) was terminated because of toxicity and efficacy issues.
Controlling the VRE burden has also proven elusive in our large medical centers with long-standing VRE endemics. Compared to many gram-negative resistant strains, acquired resistance in enterococci and most other gram-positive species is stable and indefinitely expressed. Moreover, observational studies that have shown VRE strains capable of protracted intestinal colonization, coupled with their ability to survive for at least several days in the inanimate hospital environment, makes VRE control strategies highly challenging and eradication of established endemics nearly impossible [19, 20] [23, 24] . De novo resistance or the transfer of the vanA/vanB genes to a more prevalent and virulent species such as S. aureus remains a dangerous possibility which would plunge us further into a postantibiotic era. The rapid development of novel antimicrobial compounds, coupled with a dedication to basic infection control principles and rationale antimicrobial prescription, appear to be our only tools to battle the inexorable trend so typified by the Enterococcus.
